Brought to you by:
VQI analysis of CLTI practice following BEST-CLI finds no pick up in bypass rate
A Vascular Quality Initiative (VQI) analysis of evolving practice in the wake of the BEST-CLI trial demonstrated no increase in the rate of surgical bypass in the year afterwards. More analysis needs to be done comparing the data pre- and…
‘Choosing the right devices for the right patients’: Surgeon-scientist secures NIH funding to develop MRI technique for precision PAD care
Michael Conte, MD, recently used his 2024 Veith Lecture to call on young vascular surgeons on the peripheral arterial disease (PAD) frontlines to drive the space forward amid a great unmet need. The professor and chief of vascular and endovascular…
Sex-based analysis finds BEST-CLI data generalizable to female patients
A new secondary analysis of sex disparities in the best endovascular versus best surgical therapy in patients with critical limb ischemia (BEST-CLI) trial data has found that improved major adverse limb event (MALE)-free survival via open surgical bypass with single…
Sex-based analysis finds BEST-CLI data generalizable to female patients
A new secondary analysis of sex disparities in the best endovascular versus best surgical therapy in patients with critical limb ischemia (BEST-CLI) trial data has found that improved major adverse limb event (MALE)-free survival via open surgical bypass with single…
Vascular surgery trainees face the future armed similarly with both open and endovascular skills
The BEST-CLI trial underscores the importance of ensuring trainee competence in open peripheral revascularization as well as endovascular treatment. Indeed, the trial results have called for a reshift in focus to ensure trainees have much needed open skills. That’s because,…
BEST-CLI and the BASIL trials: Motion sees audience move in favor of endovascular therapy over bypass
During the 2024 Charing Cross (CX) International Symposium in London, England (April 23–25), a Great Debate that pitted four global peripheral arterial disease (PAD) heavyweights against one another yielded an audience vote that went against the motion, “Bypass surgery is…
Endovascular showdown: CX 2024 sets the stage for BASIL-3 first-time data presentations
At the Charing Cross (CX) Symposium 2024 (23–25 April, London, UK), Andrew Bradbury (University of Birmingham, Birmingham, UK) and the BASIL-3 team of triallists will address the pressing question of which endovascular strategy wins in the disputed femoropopliteal segment. The…
Landmark BEST-CLI trial gains recognition as top cardiovascular advance in 2023
The American Heart Association (AHA) has named the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) trial one of the top cardiovascular advances of 2023. This study—led by vascular surgeons Alik Farber, MD, and Matthew…
The top 10 most popular Vascular Specialist stories of January 2024
In January, the most read stories from Vascular Specialist include a U.S. Aortic Research Consortium analysis of F/BEVAR preoperative risk factors in AAAs/TAAAs; a reflection on lessons learnt one year on from BEST-CLI; Southern Vascular’s election of its first female…
BEST-CLI: A year down the road
A dedicated session at the 2023 VEITHsymposium (Nov. 14–18) in New York City aimed to unpack the ways in which clinical practice and attitudes in the field of chronic limb-threatening ischemia (CLTI) have changed since the BEST-CLI trial was published…